There are general problems in treating advanced malignant disease of the pelvis. The patient may be very well above the waist but suffer pain and disability below this level. The terminal care phase can seem very lengthy to the patient, especially if the medical and paramedical attention is inadequate. The patient requires to be assessed physically, mentally and socially, and management should be carefully directed as specifically as possible.
Drugs are the main stand-by of treatment and should be used in the context of the assessment. Among the analgesics oral methadone is an especially valuable drug. Tranquillizers may be doubly useful if they have anti-emetic effects. The antidepressant effects of steroids may be helpful or more specific drugs such as amitriptyline can be used. Hypnotics may include alcohol. Diuretics may help the swollen leg. Aperients are often the most acceptable group of drugs.
Simple psychotherapy is valuable in terminal illness and hypnotherapy may be worthy of trial if the practitioner is interested and the patient receptive. Hypnotherapy may vary from mild relaxation to removal of painful sensations. Good medical social welfare is vital in order to utilize all the available social benefits, both voluntary and of the National Health Service.
Nerve blocking may be worth considering. The intractable pain is usually in the sacral and lower lumbar root distribution. Local anaesthetic blocks give a diagnostic and prognostic indication of the likely relief of pain, and on occasion they are successful for days or weeks. In a series of 80 patients with pelvic cancer and with lumbosacral root pain, nearly half were managed with drugs and/or local anmsthetic blocks. Seven patients in this series had a total of 13 intrathecal blocks with hypertonic saline, but none had lasting relief of pain. This is best done under a general anesthetic as it is an uncomfortable procedure for the patient.
Thirty-seven patients had 83 blocks with intrathecal phenol, and 4 patients had 7 blocks with intrathecal alcohol. The patient was usually conscious during these injections, but general anesthesia should be considered if the patient finds the position required for the injection painful, or difficult to achieve and hold while the neurolytic agent fixes. The complicating risks of these blocks are parmsthesia, proprioceptive loss, motor paresis due to involvement of motor roots, and sphincter disturbance. Only 3 patients had complications which they reckoned severe, and they were not aware of their prognosis. There were 20 patients who had complications of a mild nature. Sixteen patients were classified as having good relief of pain from the intrathecal alcohol or phenol blocks, 23 were rated as having a satisfactory relief of pain, and 2 patients said they had no relief. Because of this latter small group it may be worth doing a spinal anmsthetic first to establish whether the intractable pain is relievable by an intrathecal chemical nerve blocking agent in the lumbosacral area. Two patients were referred for anterolateral chordotomy after phenol blocks. At the present time, the use of specific antitumour agents in the management of patients with advanced rectal cancer is very disappointing. No drug has yet been identified which will reliably retard or reverse the growth of adenocarcinoma of the gastrointestinal tract. Some of the drugs currently available will produce an effect in certain patients but the responses are not predictable and often only short-lived. I have reported previously findings concerning the blood supply of primary tumours of the large intestine and the accessibility of drugs to them (McKinna 1967 , Smart 1968 . In particular there are large areas in the centre of many of these tumours which are not easily reached by cytotoxic drugs even when they are administered by close arterial injection. These findings must be applicable to the extensive pelvic disease of the advanced primary tumour or of the recurrent case and, in the face of a poor therapeutic response, chemotherapy must be related to the other treatments available and particularly to palliative surgery.
Locally Advanced Disease Pelvic arterial infusion may be the route of choice and it can be carried out at the time of operation. A 50-year-old Arab was referred in 1968 with an advanced anaplastic tumour of the rectum which was invading the prostate and the pelvic wall. At laparotomy, 50 mg nitrogen mustard (mustine) was injected into the superior rectal artery and a left iliac colostomy established. Fifteen days later he passed per rectum a large quantity of tumour in the form of a necrotic cast. His symptoms of urgency and of discharge of blood and mucus were considerably relieved.
Drugs may be administered through a low intra-aortic catheter passed by the retrograde femoral (Seldinger) technique. A single dose may be given at the time or repeated doses may be given over a period of days. This latter method carries with it the hazards of an arterial drip, but it may be more satisfactory in terms of the remission obtained. The results of 19 low aortopelvic infusions in 14 patients with inoperable or recurrent rectal cancer have been reported (J A McKinna, J D Griffiths & J E Ind 1965, unpublished communication). The technique involved injection of drug into a fast-running aortic drip with concurrent pressure-cuff occlusion of both femoral arteries.
In 14 courses of treatment, nitrogen mustard was used -10 mg daily for 3-10 doses over periods up to 10 days (0-2-1-0 mg/kg body weight). The injection always provoked intense nausea and often exacerbated briefly the pelvic pain from which the patient suffered. These effects were reduced by premedication with 20 mg Omnopon and 10 mg perphenazine intramuscularly. The latter was given with the mustard and repeated as necessary in the next 2-4 hours. A temporary leukopenia was always seen in the next two weeks. Nearly all patients had relief of pain lasting from 3 weeks to 3 months but objective regression of tumour was rarely seen.
In five courses, 5-fluorouracil was infused in a dosage of 750 mg per day for 5 days (10-15 mg/kg per day to a total dose of 3-75 g). Pain was relieved in all cases and nausea only encountered once. The duration of the relief was from 3 to 6 weeks.
Disseminated Disease
Here it may be possible to help the patient with systemic chemotherapy but it is important to remember that in the absence of symptoms the treatment may be worse than the disease. Using 5-fluorouracil, Ansfield has claimed remissions averaging 6 months in duration (Ansfield et al. 1962 ). Zubrod points out that an objective assessment of remission is difficult, particularly with recurrent pelvic disease (Zubrod 1961). A useful dosage schedule is 15 mg/kg 5-fluorouracil by daily intravenous injection for 5-7 days, taking care to stop if toxic signs appear (stomatitis, diarrhoea, thrombocytopenia or leukopenia). A similar course may be given after an interval of a month, or single weekly injections of 15 mg/kg may be given after heematological check. This has the advantage of avoiding hospital admission in the patient's last months of life. Ansfield has pointed out groups of 'poorrisk' patients, including those in poor nutritional state, those who have had previous radiotherapy or alkylating agents and those with extensive liver metastases; it is important to remember the frequent, albeit temporary, help which can be given to these patients by the judicious use of corticosteroids.
Of the alkylating agents, cyclophosphamide is common amongst the small group of drugs used in systemic therapy. It carries the risk of alopecia, particularly after high intravenous loading dosos, but oral maintenance therapy is simple to manage with hematological control. Remission is infrequent. This drug has been used as an adjuvant to radical curative surgery with followup therapy (Blixenkrone-Moller 1964). An increased survival has bean reported in colonic but not in rectal carcinoma; nevertheless it is in the field of adjuvant therapy that these drugs may yet play their most important part in improving the results of surgery (reported by Mr H J R Bussey, p 1221).
Conclusion
Antitumour drugs may be of use in the management of rectal cancer. Their effect seems to be limited and their use should probably be reserved for those patients with distressing symptoms such as pain.
